Laboratory for Cancer Immunotherapy, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Department of Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA, 92093-0687, USA.
Cell Mol Life Sci. 2020 Feb;77(4):593-605. doi: 10.1007/s00018-019-03288-x. Epub 2019 Sep 4.
The mammalian immune system evolved to tightly regulate the elimination of pathogenic microbes and neoplastic transformed cells while tolerating our own healthy cells. Here, we summarize experimental evidence for the role of Siglecs-in particular CD33-related Siglecs-as self-receptors and their sialoglycan ligands in regulating this balance between recognition of self and non-self. Sialoglycans are found in the glycocalyx and extracellular fluids and matrices of all mammalian cells and can be considered as self-associated molecular patterns (SAMPs). We also provide an overview of the known interactions of Siglec receptors and sialoglycan-SAMPs. Manipulation of the Siglec-SAMP axis offers new therapeutic opportunities for the treatment of inflammatory conditions, autoimmune diseases and also cancer immunotherapy.
哺乳动物的免疫系统经过进化,能够在清除病原微生物和肿瘤转化细胞的同时,严格调控对自身健康细胞的耐受性。在这里,我们总结了实验证据,证明 Siglec(尤其是 CD33 相关 Siglec)作为自身受体及其唾液酸糖蛋白配体在调节自我识别与非自我识别之间的平衡方面发挥着重要作用。唾液酸糖蛋白存在于所有哺乳动物细胞的糖萼和细胞外液及基质中,可以被视为自身相关的分子模式(SAMPs)。我们还概述了已知的 Siglec 受体与唾液酸糖蛋白-SAMPs 的相互作用。对 Siglec-SAMP 轴的操纵为治疗炎症性疾病、自身免疫性疾病和癌症免疫治疗提供了新的治疗机会。